Systematic Review and Critical Analysis of Cost Studies Associated with Parkinson’s Disease
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease worldwide, affecting more than four million people. Typically, it affects individuals above 45, when they are still productive, compromising both aging and quality of life. Therefore, the cost of the disease must be iden...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2017-01-01
|
Series: | Parkinson's Disease |
Online Access: | http://dx.doi.org/10.1155/2017/3410946 |
id |
doaj-cd0156f238434dfba19a68ea683c6740 |
---|---|
record_format |
Article |
spelling |
doaj-cd0156f238434dfba19a68ea683c67402020-11-24T20:46:40ZengHindawi LimitedParkinson's Disease2090-80832042-00802017-01-01201710.1155/2017/34109463410946Systematic Review and Critical Analysis of Cost Studies Associated with Parkinson’s DiseaseTânia M. Bovolenta0Sônia Maria Cesar de Azevedo Silva1Roberta Arb Saba2Vanderci Borges3Henrique Ballalai Ferraz4Andre C. Felicio5Programa de Pós-Graduação, Hospital Israelita Albert Einstein, São Paulo, SP, BrazilMovement Disorders Department in Neurology, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, BrazilUniversidade Federal de São Paulo (UNIFESP), São Paulo, SP, BrazilUniversidade Federal de São Paulo (UNIFESP), São Paulo, SP, BrazilUniversidade Federal de São Paulo (UNIFESP), São Paulo, SP, BrazilNeurology Program, Hospital Israelita Albert Einstein, São Paulo, SP, BrazilParkinson’s disease (PD) is the second most prevalent neurodegenerative disease worldwide, affecting more than four million people. Typically, it affects individuals above 45, when they are still productive, compromising both aging and quality of life. Therefore, the cost of the disease must be identified, so that the use of resources can be rational and efficient. Additionally, in Brazil, there is a lack of research on the costs of neurodegenerative diseases, such as PD, a gap addressed in this study. This systematic review critically addresses the various methodologies used in original research around the world in the last decade on the subject, showing that costs are hardly comparable. Nonetheless, the economic and social impacts are implicit, and important information for public health agents is provided.http://dx.doi.org/10.1155/2017/3410946 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Tânia M. Bovolenta Sônia Maria Cesar de Azevedo Silva Roberta Arb Saba Vanderci Borges Henrique Ballalai Ferraz Andre C. Felicio |
spellingShingle |
Tânia M. Bovolenta Sônia Maria Cesar de Azevedo Silva Roberta Arb Saba Vanderci Borges Henrique Ballalai Ferraz Andre C. Felicio Systematic Review and Critical Analysis of Cost Studies Associated with Parkinson’s Disease Parkinson's Disease |
author_facet |
Tânia M. Bovolenta Sônia Maria Cesar de Azevedo Silva Roberta Arb Saba Vanderci Borges Henrique Ballalai Ferraz Andre C. Felicio |
author_sort |
Tânia M. Bovolenta |
title |
Systematic Review and Critical Analysis of Cost Studies Associated with Parkinson’s Disease |
title_short |
Systematic Review and Critical Analysis of Cost Studies Associated with Parkinson’s Disease |
title_full |
Systematic Review and Critical Analysis of Cost Studies Associated with Parkinson’s Disease |
title_fullStr |
Systematic Review and Critical Analysis of Cost Studies Associated with Parkinson’s Disease |
title_full_unstemmed |
Systematic Review and Critical Analysis of Cost Studies Associated with Parkinson’s Disease |
title_sort |
systematic review and critical analysis of cost studies associated with parkinson’s disease |
publisher |
Hindawi Limited |
series |
Parkinson's Disease |
issn |
2090-8083 2042-0080 |
publishDate |
2017-01-01 |
description |
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease worldwide, affecting more than four million people. Typically, it affects individuals above 45, when they are still productive, compromising both aging and quality of life. Therefore, the cost of the disease must be identified, so that the use of resources can be rational and efficient. Additionally, in Brazil, there is a lack of research on the costs of neurodegenerative diseases, such as PD, a gap addressed in this study. This systematic review critically addresses the various methodologies used in original research around the world in the last decade on the subject, showing that costs are hardly comparable. Nonetheless, the economic and social impacts are implicit, and important information for public health agents is provided. |
url |
http://dx.doi.org/10.1155/2017/3410946 |
work_keys_str_mv |
AT taniambovolenta systematicreviewandcriticalanalysisofcoststudiesassociatedwithparkinsonsdisease AT soniamariacesardeazevedosilva systematicreviewandcriticalanalysisofcoststudiesassociatedwithparkinsonsdisease AT robertaarbsaba systematicreviewandcriticalanalysisofcoststudiesassociatedwithparkinsonsdisease AT vanderciborges systematicreviewandcriticalanalysisofcoststudiesassociatedwithparkinsonsdisease AT henriqueballalaiferraz systematicreviewandcriticalanalysisofcoststudiesassociatedwithparkinsonsdisease AT andrecfelicio systematicreviewandcriticalanalysisofcoststudiesassociatedwithparkinsonsdisease |
_version_ |
1716811892804026368 |